Meeting
2020 ASCO Virtual Scientific Program
Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211).
Presenter
Saad Zafar Usmani, MD, FACP
Levine Cancer Institute, Atrium Health
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT01668719
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8507)
DOI
10.1200/JCO.2020.38.15_suppl.8507
Abstract #
8507
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Annual Meeting
Phase II study of umbilical cord blood–derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM).
Speaker: Samer Ali Srour, MBChB, MS
Videos & Slides
2017 ASCO Annual Meeting
Lenalidomide, doxorubicin hydrochloride, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone prior to scheduled stem cell transplant in newly diagnosed myeloma.
Speaker: Stefan Knop, MD
Videos & Slides
2015 ASCO Annual Meeting
Industry Perspectives: Toward Fair and Fruitful Interactions
Speaker: Richard Gaynor, MD
Videos & Slides
2011 ASCO Annual Meeting
